Coherus BioSciences

Coherus' Chief Development Officer, Theresa LaVallee, PhD, is participating in a panel session on "Navigating IO Drug Development for Biotechs in a Saturated Field: Insights and Strategies" at the 11th #IO360Summit in Boston next week. This session will guide biotechs through IO drug development amidst a saturated landscape and delve into tailored approaches for IO-focused companies, addressing challenges and charting pathways for successful advancement in the field.

Attending #IO360Summit? Meet with Coherus’ Chief Development Officer, Theresa LaVallee and EVP, Corporate Development, Scott Saywell to learn more about the exciting developments in our novel oncology pipeline. We look forward to seeing you in Boston!

Dr Theresa LaVallee, Chief Development Officer of Coherus BioSciences, recently shepherded their drug toripalimab through a challenging approval process. She tells us what is next for the drug, the challenges facing medicine developers, and what keeps her enthusiastic about immuno-oncology. 🔗 Read the interview here: https://lnkd.in/eb-ty6dn #IO360Summit

Join us for our Q4-FY 2024 earnings call today, starting at 5:00 pm ET, to hear about our Q4 financial results and recent business highlights. Press release: https://bit.ly/41DvYa7 and Listen to the webcast: https://bit.ly/4hlVgQ9

Coherus will report Q4 and Full Year 2024 financial results on March 10, 2025. Starting at 5 pm EST, CEO Denny Lanfear and the executive team will host a conference call and webcast to discuss Q4-FY 2024 financial results and recent business highlights. Webcast link: https://bit.ly/4hlVgQ9

Coherus will report Q4 and Full Year 2024 financial results on March 10, 2025. Starting at 5 pm EST, CEO Denny Lanfear and the executive team will host a conference call and webcast to discuss Q4-FY 2024 financial results and recent business highlights. Webcast link: https://bit.ly/4hlVgQ9

Coherus CEO Denny Lanfear and Chief Development Officer Theresa LaVallee will participate in a fireside chat presentation with Michael Nedelcovych at TD Securities Cowen Health Care Conference on Tuesday, March 4th at 11:50 am ET. Listen in via webcast: https://lnkd.in/gsxG8k8y

Coherus presented final results from our Phase 2 HCC study of casdozo in combination with atezo/bev at ASCO#GI25 today. View the poster here: https://bit.ly/40KERQ4

We look forward to Dr. Denang Li’s presentation of the final data from our Phase 2 combination study of casdozo with standard of care in patients with liver cancer on Friday at the 2025 American Society of Clinical Oncology (ASCO) GI Symposium. Casdozokitug, in combination with atezolizumab/bevacizumab, final data demonstrate the durability of response and improvement in the depth of response, including a 17.2% complete response rate. Read more about the data and the upcoming presentation in our press release: https://bit.ly/3PL5myo

Tune in today at 5:15pm PT for a company presentation from Coherus Biosciences’ CEO, Denny Lanfear, at the J.P. Morgan Healthcare Conference. A live webcast of the presentation will be available here: https://bit.ly/4hck1hY #JPM25